TSAAI 2026 Annual Meeting

Pigeon Forge, TN US
July 24, 2026 to July 26, 2026

The Tennessee Society of Allergy, Asthma and Immunology (TSAAI) was established to coordinate the efforts of specialists in allergy, asthma and immunology in the state of Tennessee, principally for scientific and education purposes and to promote the highest standards of practitioners in the fields of allergy, asthma and immunology.

TSAAI's annual educational meeting consists of presentations by recognized speakers in the field of allergy, asthma and immunology.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunology and the Tenessee Society of Allergy, Asthma & Immunology (TSAAI). The American College of Allergy, Asthma & Immunology is accredited by the ACCME to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 8 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

No commercial support was received for this activity.

Target Audience

All practicing allergists/immunologists
Fellows in allergy/immunology training programs
NPs and PAs in the field of allergy and immunology

Learning Objectives

At the conclusion of this Activity learners should be able to…
1.    Describe key pathogenic mechanisms of CSU, including type 2 inflammation, autoimmunity, and mast cell activation pathways.
2.    Discuss newer therapies approved for CSU, such as omalizumab, dupilumab, and remibrutinib, focusing on their indications and efficacy in refractory cases.
3.    Describe novel therapeutic approaches for CSU in clinical development, including BTK inhibitors and anti-KIT antibodies.
4.    Describe the various phenotypes of antibody deficiency as defined in the 2025 Practice Parameters for Inborn Errors of Immunity.
5.    Evaluate patients for antibody deficiency using current clinically available immunizations.
6.    Interpret laboratory tests for antibody deficiency.
7.    Evaluate genetic test results for allergic and immunologic diseases, resolving variants of uncertain significance (VUS) through clinical correlation and functional studies.
8.    Compare biologic therapies for severe asthma, including omalizumab, dupilumab, and anti-IL-5 agents, based on biomarkers like eosinophils and FeNO.
9.    Separate HAE medications by understanding MOA and prescribe the right medication for each individual patient.
10.    Diagnose AD in complex patients and use the appropriate topical or systemic therapy.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Course opens: 
07/24/2026
Course expires: 
12/31/2026
Event starts: 
07/24/2026 - 4:00pm CDT
Event ends: 
07/26/2026 - 12:30pm CDT
Add to calendar: 
Rating: 
0

TSAAI 2026 Annual Meeting
Dollywood’s HeartSong Conference Center, Pigeon Forge, TN
July 24-26, 2026

Saturday, July 25, 2026
All CME Sessions will be held in Salon C/D

7:35 am    Welcome                                  
7:45 – 8:45 am    We are Living in a Prevnar World: How to Diagnose Antibody Deficiency in 2026/Q&A - Dr. Monica Lawrence               
8:45 – 9:45 am    HAE/Q&A - Dr. Marc Riedl    
9:45 – 10:15 am    Break & exhibits (Salon A/B)
10:15 – 11:15 am    Asthma and COPD/Q&A - Dr. Monica Kraft
12:00 – 1:00 pm    Panel Discussion: Battle of the Biologics/Q&A - Dr Tom Casale, Dr. Monica Kraft & Dr. Dennis Ledford    

Sunday, July 26, 2026
All CME Sessions will be held in Salon C/D

8:00 – 9:00 am    What to Do When Your Biologic is Not Working In an Adult with Severe Asthma/Q&A - Dr. Dennis Ledford      
9:00 – 10:00 am    Atopic Dermatitis: When Guidelines Can’t Keep Up/Q&A - Dr. Mark Boguniewicz        
10:00 – 10:30 am    Break & exhibits (Salon A/B)
10:30 – 11:30 am    Urticaria/Q&A - Dr. Tom Casale    
11:30 – 12:30 pm    Genetic Tests for Allergic and Immunologic Diseases and How to Resolve a Variant of Uncertain Significance/Q&A - Dr. Jolan Walter                                                 
12:30 pm    Meeting adjourn
    *please stay for a short business meeting & door prize drawing

Dollywood HeartSong Conference Center
1210 Dollywood Resorts Blvd
Pigeon Forge, TN 37863
United States

All relevant financial relationships with ineligible companies have been mitigated.

Mark Boguniewicz, MD, Speaker
Advisor: Amgen, Arcutis, Dermanvant/Organon, Enveda, Galderma, lncyte, LEO Pharma, Lilly, Pfizer, Regeneron, Sanofi; Researcher: Regeneron, Sanofi

Thomas Casale, MD, Speaker
Advisor: Novartis; Consultant: AstraZeneca, Celldex, Eli Lilly, Escient, Genentech, Jasper, Sanofi/Regeneron Researcher: Eli Lilly; Speaker: Sanofi/Regeneron, Genentech

Nicholas Kolinsky, DO, Program Chair and Planner
Advisor: ADMA Biologics, AstraZeneca, Blueprint Medicines, Hikma, lncyte Corporation, Kalvista, Pharming, Novartis; Consultant: ADMA Biologics, AstraZeneca, Blueprint Medicines, Hikma, lncyte Corporation, Kalvista, Novartis, Pharming; Speaker: Amgen, AstraZeneca, CSL Behring, Eli Lilly and Company, Galderma, GlaxoSmithKline, Grifols, lonis Pharmaceuticals, Hikma, Kalvista, Novartis, Regeneron, Sanofi Pharmaceuticals

Monica Lawrence, MD
Consultant: Pharming, ADMA Biologics

Monica Kraft, MD, Speaker
Consultant: AstraZeneca, Sanofi, GSK, Regeneron, Uniquity Bio; Researcher: Sanofi; Speaker: Chiesi, AstraZeneca, Sanofi, GSK

Dennis Ledford, MD, Speaker
Speaker: GSK, Novartis, Sanofi/Regeneron Independent Contractor: AstraZeneca, Novartis

Marc Riedl, MD MS, Speaker
Consultant: ADARx, Astria, CSL Behring, Grifols, lntellia, lonis, Kalvista, Pharming, Pharvaris; Researcher: Astria, CSL Behring, lonis, lntellia, Kalvista, Pharvaris; Speaker: CSL Behring, Grifols, Pharming, Pharvaris

Jolan Walters, MD, Speaker
Advisor: ADMA Biologics, Chiesi, Grifols, Novartis, Pharming Healthcare, X-4 Pharmaceuticals, Takeda Consultant: ADMA Biologics, Chiesi, Grifols, Novartis, Pharming Healthcare, X-4 Pharmaceuticals, Takeda; Researcher: Orea Bio, Grifols, Takeda, Octapharma, X-4 Pharmaceuticals, Bristol-Myers Squibb; Speaker: Pharming, Takeda

Monica Kraft, MD, Speaker
Consultant: AstraZeneca, Sanofi, GSK, Regeneron, Uniquity Bio; Researcher: Sanofi; Speaker: Chiesi, AstraZeneca, Sanofi, GSK

Dennis Ledford, MD, Speaker
Speaker: GSK, Novartis, Sanofi/Regeneron Independent Contractor: AstraZeneca, Novartis

Marc Riedl, MD MS, Speaker
Consultant: ADARx, Astria, CSL Behring, Grifols, lntellia, lonis, Kalvista, Pharming, Pharvaris; Researcher: Astria, CSL Behring, lonis, lntellia, Kalvista, Pharvaris; Speaker: CSL Behring, Grifols, Pharming, Pharvaris

Jolan Walters, MD, Speaker
Advisor: ADMA Biologics, Chiesi, Grifols, Novartis, Pharming Healthcare, X-4 Pharmaceuticals, Takeda Consultant: ADMA Biologics, Chiesi, Grifols, Novartis, Pharming Healthcare, X-4 Pharmaceuticals, Takeda; Researcher: Orea Bio, Grifols, Takeda, Octapharma, X-4 Pharmaceuticals, Bristol-Myers Squibb; Speaker: Pharming, Takeda

The following have no relevant financial relationships to disclose:
Karthik Krishnan, MD, Program Chair, Planner
Michelle Kittle, Meeting Coordinator
 

 

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Attendance
Please login or create an account to take this course.